Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus.-Reference-Cited by-同舟云学术

Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus.

Published:1992-02-01 Issue:2 Volume:51 Page:152-155
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Annals of the Rheumatic Diseases

Author:

MacGregor A J,Dhillon V B,Binder A,Forte C A,Knight B C,Betteridge D J,Isenberg D A

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Reference30 articles.

1. Coronary arteritis, occlusion and myocardial infarction due to lupus erythematosus. Am Heart3';A, Bonfiglio T.; E, Botti R.; W, Hagstrom J.,1972

2. Ischaemic heart disease in SLE in young patients; report of six cases;J, Homcy C.; R, Liberthson R.; T, Fallon J.; S, Gross; M, Miller L.;Am J Cardiol,1982

3. Myocardial infarction in four young patients with SLE;Spiera, H.; Rothenburg, R.;J Rheumatol,1983

4. SLE and acute myocardial infarction;Jensen, G.; Sigurd, B.;Chest,1973

5. Coronary arterial disease in SLE: quantification of degree of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years;S, Haider Y.; C, Roberts W.;AmJ Med,1981

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atherosclerosis in Systemic Lupus Erythematosus;Current Atherosclerosis Reports;2023-09-28

2. Synthetic Pharmacotherapy for Systemic Lupus Erythematosus: Potential Mechanisms of Action, Efficacy, and Safety;Medicina;2022-12-27

3. Is there a safe and effective way to wean patients off long‐term glucocorticoids?;British Journal of Clinical Pharmacology;2021-01

4. Cardiovascular Risk Assessment and Impact of Medications on Cardiovascular Disease in Inflammatory Bowel Disease;Inflammatory Bowel Diseases;2020-09-26

5. Predisposing factors to nonfatal cardiovascular events in women with systemic lupus erythematosus. An observational, cross-sectional, multicenter study in Spain from the risk/systemic lupus erythematosus thematic network;Medicine;2019-10